Deep search
Rewards
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
U.S.
2024 Election
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
FDA expands approval of breast cancer drug Kisqali
FDA OKs Adjuvant Ribociclib in Earlier Stage Breast Cancer
Unlike rival CDK 4/6 inhibitor abemaciclib, patients don't need to be lymph-node positive to receive ribociclib after surgery.
Major New Drug Approval For Preventing Recurrence In Early Stage Breast Cancer Patients: Weighing The Risks & Benefits of Kisqali
The Food and Drug Administration (FDA) has just approved the drug Kisqali (ribociclib) in combination with an aromatase inhibitor (AI) as treatment for people with HR+/HER2- stage II and III early breast cancer (EBC) at high risk of recurrence.
Kisqali wins FDA nod for breast cancer treatment: Dosage, effectiveness and side effects of the breakthrough drug
The US FDA has approved Kisqali (ribociclib) for treating early-stage breast cancer in combination with hormone therapy. It targets high-risk HR-posit
The American Journal of Managed Care
3d
FDA Approves Ribociclib for Early Breast Cancer Treatment With High Recurrence Rate
The FDA approved
ribociclib
(Kisqali) for adjuvant treatment of high-risk, hormone receptor-positive, HER2-negative early
breast
cancer
. The FDA approved
ribociclib
(Kisqali) with an aromatase ...
Targeted Oncology
1d
Dual HER2 Blockade Plus Ribociclib Offers Chemo-Free Option in HR+/HER2+ Breast Cancer
Combining endocrine therapy with the dual HER2 blockade of trastuzumab and pertuzumab and the CDK4/6 inhibitor ribociclib ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Trending now
Kentucky judge fatally shot
Body found in SUV
Secret Service probing post
FCC chair denies Trump call
Cancels appearance w/ Duda
Boy kills bear, saves father
NYC subway joyride arrest
To visit US next week
Ban called for in TX schools
Man charged for threats
Hold campaign event in MI
Families lose appeal
To get a second moon
Vows to remain in race
Collapse hazard recall
Hails economic progress
Dow, S&P hit record highs
Existing home sales drop
Brazil threatens daily fines
160M euros to Ukraine
PGA welcomes LIV players
FTC on privacy controls
Retires after 17 seasons
UN backs Palestine
Israel strikes Hezbollah
Gun case sentencing delay
EU warns Apple
Overdose deaths drop in US
COVID, Wuhan market link
To receive Holbrooke award
Makes MLB history
Feedback